Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial

AIDS and Behavior

Volumn 19, Issue 5, 2015, Pages 770-783

  van der Straten, Ariane ^a,b   Mayo, Ashley ^c   Brown, Elizabeth R ^d,f   Amico, K Rivet ^e   Cheng, Helen ^a   Laborde, Nicole ^a   Marrazzo, Jeanne ^f   Torjesen, Kristine ^c  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c FAMILY HEALTH INTERNATIONAL   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF CONNECTICUT   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adherence; Counseling staff; HIV prevention trial; Intervention; Microbicides; PrEP

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TENOFOVIR;

ADULT; BLOOD; COUNSELING; FEMALE; HIV INFECTIONS; HUMAN; INTERVIEW; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PATIENT ATTITUDE; PERCEPTION; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES; PSYCHOLOGY; QUALITATIVE RESEARCH; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA;

ADULT; ANTI-HIV AGENTS; COUNSELING; FEMALE; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PERCEPTION; PRE-EXPOSURE PROPHYLAXIS; QUALITATIVE RESEARCH; SURVEYS AND QUESTIONNAIRES; TENOFOVIR;

EID: 84939957849     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-014-0945-2     Document Type: Article

References (26)

1. Baeten JM, Grant R. Use of antiretrovirals for HIV prevention: what do we know and what don’t we know? Curr HIV/AIDS Rep. 2013;10:142–51.
2. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS (London, England). 2012;26(7):F13–9.
3. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.
4. Karim QA, Karim SSA, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–74.
5. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. NEJM. 2012;367:399–410.
6. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. NEJM. 2012;367(5):423–34.
7. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the bangkok tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.
8. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. NEJM. 2012;367:411–22.
9. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofoviremtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). CROI. March 3–6, 2013; Atlanta GA2013.
10. Hendrix CW. Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design. Cell. 2013;155(3):515–8.
11. Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014;59(Suppl 1):s55–s60.
12. Amico KR, Mansoor L, Corneli A, Torjesen K, van der Straten A. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;17:2143–55.
13. Koenig LJ, Lyles C, Smith DK. Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: lessons learned from trials and treatment studies. Am J Prev Med. 2013;44(1 Suppl 2):S91–8.
14. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Pre-exposure prophylaxis for HIV in women: Daily oral tenofovir, oral tenofoviremtricitabine, or vaginal tenofovir gel in the voice study (mtn 003). NEJM. 2014 forthcoming.
15. Amico K, McMahan V, Goicochea P, Vargas L, Marcus JL, Grant RM, et al. Supporting study product use and accuracy in self-report in the IPREX study: next step counseling and neutral assessment. AIDS Behav. 2012;16(5):1243–59.
16. Microbicide trials network statement on decision to discontinue use of oral tenofovir tablets in voice, a major HIV prevention study in women. Microbicide Trials Network; 2011.
17. Microbicide trials network statement on decision to discontinue use of tenofovir gel in voice, a major HIV prevention study in women. 2011.
18. van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the voice-c qualitative study in Johannesburg, South Africa. PLoS One. 2014;9(2):e89118.
19. Hendrix CW, Andrade A, Kashuba A, Marzinke M, Anderson PL, Moore A, et al. Tenofovir-emtricitabine directly observed dosing: 100 % adherence concentrations (hptn 066). 21st Conference on Retorviruses and Opportunistic Infections; March 3–6; Boston, 2014.
20. Schwartz JL, Rountree W, Kashuba ADM, Brache V, Creinin MD, Poindexter A, et al. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1 % tenofovir gel. PLoS One. 2011;6(10):e25974.
21. Mansoor LE, Karim QA, Werner L, Madlala B, Ngcobo N, Cornman DH, et al. Impact of an adherence intervention on the effectiveness of tenofovir gel in the Caprisa 004 trial. AIDS Behav. 2014;18(5):841–8.
22. Mansoor LE, Abdool Karim Q, Yende-Zuma N, MacQueen KM, Baxter C, Madlala BT, et al. Adherence in the Caprisa 004 tenofovir gel microbicide trial. AIDS Behav. 2014;81:811–9.
23. Dewing S, Mathews C, Schaay N, Cloete A, Louw J, Simbayi L. Behaviour change counseling for arv adherence support within primary health care facilities in the Western Cape, South Africa. AIDS Behav. 2012;16:1286–94.
24. Schwartz K, Ndase P, Torjesen K, Mayo A, Scheckter R, van der Straten A, et al. Supporting participant adherence through structured engagement activities in the MTN-020 (aspire) trial. Community Engagement in Prevention Research, HIV Research for Prevention 2014 (HIV R4P); Cape Town, South Africa, October 28–31, 2014.
25. Corneli A, Perry B, Agot K, Ahmed K, McKenna K, Malamatsho F, et al. Fem-prep: participant explanations for non-adherence. Conference on Retroviruses and Opportunistic Infections; Boston, Mass. 2014.
26. van der Straten A, Montgomery E, Hartmann M, Levy L, Piper J, Mensch B. Strategies to explore factors impacting study product adherence among women in VOICE. IAPAC Conference; June 8–10, 2014; Miami, Florida. 2014.